

## C.V.



Oh, Sang Cheul M.D., Ph.D.

- Male, Married
- Address: 148, Guro-dong ro, Guro-Gu, Seoul, Korea 152-703
- E-mail : sachoh@korea.ac.kr
- Phone : 02-2626-3060 Fax : 02-862-4453

### Current Position

- Professor, Division of Hematology/Oncology, Internal Medicine Department. College of Medicine, Korea University
- Member of Korea Society of Cancer

### Previous Affiliation

- 2015.9 – 2018.1; subcommittee member of president bioethics
- 2013.11 – current: A committee member for The Korea Association of Internal Medicine
- 2013.9 – current: A committee member for The Korea Health Industry Development Institute (KHIDI)
- 2013.8 – current: A chairman for IRB, Korea University, Guro Hospital
- 2013.8 – current: A committee member for World Congress of Internal Medicine
- 2012.9 - current: Professor, Division of Oncology and Hematology, Department of Internal Medicine. Guro Hospital, College of Medicine, Korea University
- 2011.8 – current: Korea University, Guro Hospital, A chairman for drug-response monitoring committee
- 2011.3 – current: KAIRB director and a chairman for education
- 2009.11 - 2010.8.: Visiting association professor, Systems Biology, MD Anderson Cancer Center, Houston, Texas
- 2008.3 - 2012.2: Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine. Guro Hospital, College of Medicine, Korea University
- 2005.3 - 2008.3: Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine. Guro Hospital, College of Medicine, Korea University
- 2004.3 – 2005.2: Postdoctoral fellow, GI Medical Oncology, MD Anderson Cancer Center
- 2003.3 – 2004.2: Clinical Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine. Guro Hospital, College of Medicine, Korea University
- 2001.5 – 2003.2: Clinical Instructor, Department of Internal Medicine. College of

Medicine, Korea University

### **Education and Training**

- Medical Doctor : College of Medicine Korea University 1993, No, 49878
- Ph.D : Postgraduate School, College of Medicine. 2002
- Residency of Internal Medicine: Korea University Hospital, Seoul, Korea 1994-1998
- Internship: Korea University Hospital , Seoul Korea 1993-1994

### **Certification**

- License of Medicine: Seoul, Korea 1993
- Board of Internal Medicine : Korea Society of Internal Medicine : 1998
- Board of Hemato-Oncology : Korea Society of Internal Medicine : 2003

### **Clinical Trial experience**

1. Cohort study for identification of high risk factors for severe toxicities with adjuvant XXX or XXXXX after curative resection in localized advanced gastric cancer
2. An International Single-Arm Protocol To Provide Expanded Access To XXXXXXXXXXXX For The Treatment Of Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior XXXXXXXXXXXXXXXX And/Or Platinum-Containing Chemotherapy
3. Post Marketing Surveillance Study of Safety and Efficacy of XXXXX Tablets under the “New Drug Re-Examination”
4. An open-label randomized multi-center phase III study of XXXXXX plus XXXXXXXXXXXXXXXX versus XXX plus XXXXXXXXXXXXXXXX as first-line therapy in patients with advanced gastric cancer
5. A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of XXXXXXXXX in combination with XXXXXXXXX (XXXXXXXXXXXXX, XXXXXXXXXXXXXXXX and XXXXXXXX XXXX) to placebo in combination with XXXXXXXXX in second line treatment of patients with metastatic colorectal cancer
6. XXXXXXXX, Phase III Study, A Multicenter, Double-Blind, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer
7. Comparison of efficacy and tolerance between combination therapy and monotherapy as a first line chemotherapy in elderly patient with advanced gastric cancer; multicenter randomized phase 3 study

8. A Randomized Phase III Study Investigating the Role of XXXXXXXXXX duration (3 months versus 6 months) in modified XXXXXX-6 or XXXXXX Regimen as Adjuvant Therapy for Patients with Stage II/III Colon Cancer
9. A study of Korean XXX XXXXXX for evaluation of improvement on cancer-related fatigue in patients with colorectal cancer with chemotherapy: A Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Trial
10. A Randomized, Open-label, Japan-Korea Collaborative Phase 3 Study to Compare the Efficacy of XXXXXXXXXXXXX and XXXXXXXXXXXXX Combination Therapy versus XXXXXXXXXXXXX Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer
11. A multicenter, randomized, non-inferiority, open label, Phase III trial to evaluate the efficacy and safety of the combination therapy of XXXXXXXXXXXXXXX and XXXXXXXXXXXXXXX in comparison to the combination therapy of XXXXXXXXXXXXX/XXXXXX XXXX and XXXXXXXXXXXXXXX in patients with advanced gastric cancer
12. A randomized, open, multicenter phase 3 study for efficacy and safety assessment of XXXXXX (XXXX XXXXXXXXXXX) vs XXXXX®(XX XXXXXXXXXXX) in patients with metastatic or recurrent unresectable gastric cancer
13. The Registry Collecting Data on Korean Gastroenteropancreatic Neuroendocrine Tumor Patients
14. Web-based registry of Korean metastatic colorectal cancer
15. Patient Characteristics, Pain Severity, and Quality of Life in Neuropathic Cancer Pain
16. A randomized phase II study of perioperative chemotherapy plus XXXXXXXXXXXXX versus postoperative chemotherapy plus XXXXXXXXXXXXX in patients with upfront resectable hepatic colorectal metastases
17. A randomized, multicenter phase III study to assess the efficacy of XXXXXXXXXXXXX versus XXXXXXXXXXXXX in patients with recurrent or metastatic gastric cancer who progress following first-line therapy
18. Analysis of molecular biologic markers including ROMO1 in colorectal cancer tissue for demonstrating those clinical utility and test of K-RAS gene mutation by using palm PCR device
19. Expression of IGF-I R Antibody / p-IGF-I R Antibody in stomach cancer tissue
20. Clinical parameters to discriminate neoplastic fever from infectious disease in metastatic colorectal cancer
21. Risk factors for brain metastasis in patients with unresectable metastatic or recurrent colorectal cancer

22. The expression of EGFR ligand in gastric and colon cancer tissue
23. Development of mRNA-miRNA multiplex diagnostic system for prognosis and medical guideline of gastric cancer and oral cancer
24. A Phases 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of XXXXXXXX for the Prevention of Chemotherapy- Induced Nausea and Vomiting(CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy
25. A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the safety and Efficacy of XXXXXXXX for the Prevention of Chemotherapy-Induced Nausea and Vomiting(CINV) in Subjects receiving highly Emetogenic Chemotherapy
26. Prospective, multicenter, observational Study on XXXXX<sup>Ⓡ</sup> (XXXXXXX) in patients with EGFR-expressing, KRAS wild-type metastatic colorectal cancer
27. Evaluating the Safety and Efficacy of Combination Therapy with FOLFOX-4 and XXXXX Therapy Versus XXXXX alone in Patients with Recurrent, Unresectable and Advanced Gastric Cancer
28. Evaluating the Safety and Efficacy of Combination Therapy with XXXXXXX and XXXXX Therapy Versus XXXXX alone in Patients with Recurrent, Unresectable and Advanced Colorectal Cancer
29. Investigation of association between XXXX XXXXXXX and XXXXXXXX Toxicity in Korean Patients with Advanced Colorectal & Gastric Cancer treated with XXXXXXX regimen
30. A Randomized , Multicenter, Double-Blinded, Placebo-Controlled Phase 3 Study of Weekly XXXXXXX with or without XXXXXXXXXXXX Drug Product in Patients with Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy
31. A randomized, Double-Blind, Active-Controlled, Optimal Dose-Titration, Multicenter Study to Evaluate the Safety and Efficacy of XXXXXXX Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor-Related Cancer
32. Clinical usefulness and Quality of life of XXXX hydromorphone in strong opioid-naive cancer pain patients; Multicenter, prospective, open-label and observational study

### **Clinical GCP training**

Chief of Institutional Review Board of Korea University Guro Hospital  
 Committee member of Korea Associate of Institutional Review Board (KAIRB)  
 2009,6-9 Training program of AAHRPP  
 2011.8 KAIRB annual meeting lecture: risk and benefit assessment  
 2011,5,19-21 WHO-FERCAP local surveyor certification. FERCAP  
 2011,3 Korea University Guro Hospital 4 weeks course GCP training certification

2011,7 Korea University Guro Hospital GCP and IRB training  
2011,12 Korea University Anam Hospital IRB lecture: IRB History  
2011, 3,23 GCP education for Clinical Investigator Korea University Guro Hospital  
2011, 1,20, GCP education for Clinical Investigator Korea University Anam Hospital  
2011, 3,28 IRB circulation education , Korean FDA  
2011, 8,4 GCP and SOP for investigator  
2012, 2. 24 Certification of Attendance 2012 Asan Medical Center HRPC & IRB Workshop  
2013, 3. 19 GCP Training Course of Korea University Guro Hospital Clinical Trial Center  
2013 Symposium  
2014, 10.30 GCP Training Course of Korea University Guro Hospital Medicine & Gene  
Clinical Trial Center-Medical Device Clinical Trial Center

## Selected Publications

Park SH, Lee DH, Kim JL, Kim BR, Na YJ, Jo MJ, Jeong YA, Lee SY, Lee SI, Lee YY, Oh SC. Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. *Oncotarget*. 2016 Aug 9. doi: 10.18632/oncotarget.11147. [Epub ahead of print] PubMed PMID: 27517746.

Kim HJ, Lee SY, Oh SC. The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. *Front Physiol*. 2016 May 9;7:168. doi: 10.3389/fphys.2016.00168. eCollection 2016. Review. PubMed PMID: 27242542; PubMed Central PMCID: PMC4861839.

Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. *Biomed Res Int*. 2016;2016:7590245. doi: 10.1155/2016/7590245. Epub 2016 Apr 5. Review. PubMed PMID: 27127793; PubMed Central PMCID: PMC4835624.

Seo HJ, Min BW, Eo JS, Lee SI, Kang SH, Jung SY, Oh SC, Choe JG. Usefulness of (18)F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal Hernia. *Nucl Med Mol Imaging*. 2016 Mar;50(1):85-9. doi: 10.1007/s13139-015-0379-4. Epub 2015 Oct 26. PubMed PMID: 26941865; PubMed Central PMCID: PMC4762860.

Lee SY, Oh SC. Changing strategies for target therapy in gastric cancer. *World J Gastroenterol*. 2016 Jan 21;22(3):1179-89. doi: 10.3748/wjg.v22.i3.1179. Review. PubMed PMID: 26811656; PubMed Central PMCID: PMC4716029.

Kim JL, Lee DH, Na YJ, Kim BR, Jeong YA, Lee SI, Kang S, Joung SY, Lee SY, Oh SC, Min BW. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells. *Tumour Biol*. 2016 Jul;37(7):9709-19. doi: 10.1007/s13277-016-4878-4. Epub 2016 Jan 23. PubMed PMID: 26803514.

Kang EJ, Lee SY, Kim HJ, Min KH, Hur GY, Shim JJ, Kang KH, Oh SC, Seo JH, Lee SY, Kim JS. Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis. *Oncology*. 2016;90(2):103-11. doi: 10.1159/000442949. Epub 2016 Jan 20. PubMed PMID: 26785048.

Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. *Ann Oncol*. 2016 Apr;27(4):673-9. doi: 10.1093/annonc/mdv625. Epub 2016 Jan 7. PubMed PMID: 26747859; PubMed Central PMCID: PMC4803452.

Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, Oh SC, Seo JH, Kim JS. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis. *Chemotherapy*. 2016;61(1):41-50. doi: 10.1159/000440941. Epub 2015 Nov 1. PubMed PMID: 26517706.

Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. *J Gastroenterol Hepatol*. 2016 Mar;31(3):581-9. doi: 10.1111/jgh.13153. PubMed PMID: 26317322.

Lee DH, Sung KS, Guo ZS, Kwon WT, Bartlett DL, Oh SC, Kwon YT, Lee YJ. TRAIL-Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stress-Induced Signal Transduction Pathways. *J Cell Biochem*. 2016 May;117(5):1078-91. doi: 10.1002/jcb.25289. Epub 2016 Feb 5. PubMed PMID: 26212606.

Kim BR, Oh SC, Lee DH, Kim JL, Lee SY, Kang MH, Lee SI, Kang S, Joung SY, Min BW. BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. *Tumour Biol*. 2015 Dec;36(12):9475-86. doi: 10.1007/s13277-015-3681-y. Epub 2015 Jun 30. PubMed PMID: 26124007.

Hwang JS, Lee HC, Oh SC, Lee DH, Kwon KH. Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. *Tumour Biol*. 2015 Nov;36(11):8819-29. doi: 10.1007/s13277-015-3629-2. Epub 2015 Jun 11. PubMed PMID: 26063410.

Kang EJ, Choi YJ, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, Kang KW, Yu ES, Shin SW, Kim YH, Kim JS. Prognostic Factors for the Selection of Patients

Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer. *Chemotherapy*. 2014;60(2):91-8. PubMed PMID: 25720697.

Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. *Clin Cancer Res*. 2015 Jan 15;21(2):357-64. doi: 10.1158/1078-0432.CCR-14-1374. Epub 2014 Nov 11. PubMed PMID: 25388162; PubMed Central PMCID: PMC4513664.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17. PubMed PMID: 25240821.

Song MG, Seo TS, Lee CH, Kim KA, Kim JS, Oh SC, Lee JK. Comparison of Two Types of Double-J Ureteral Stents that Differ in Diameter and the Existence of Multiple Side Holes along the Straight Portion in Malignant Ureteral Strictures. *Cardiovasc Intervent Radiol*. 2015 Jun;38(3):702-8. doi: 10.1007/s00270-014-0963-5. Epub 2014 Aug 27. PubMed PMID: 25159216.

Hwang J, Kang MH, Yoo YA, Quan YH, Kim HK, Oh SC, Choi YH. The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome. *World J Surg Oncol*. 2014 Aug 21;12:268. doi: 10.1186/1477-7819-12-268. PubMed PMID: 25141859; PubMed Central PMCID: PMC4155123.

Shim J, Seo TS, Song MG, Cha IH, Kim JS, Choi CW, Seo JH, Oh SC. Incidence and risk factors of infectious complications related to implantable venous-access ports. *Korean J Radiol*. 2014 Jul-Aug;15(4):494-500. doi: 10.3348/kjr.2014.15.4.494. Epub 2014 Jul 9. PubMed PMID: 25053910; PubMed Central PMCID: PMC4105813.

Kim HS, Lee SY, Oh SC, Choi CW, Kim JS, Seo JH. Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer. *Cancer Res Treat*. 2014 Jul;46(3):317-21. doi: 10.4143/crt.2014.46.3.317. Epub 2014 Jul 15. PubMed PMID: 25038768; PubMed Central PMCID: PMC4132448.

Park JH, Lee SW, Kim HS, et al. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. *Cancer chemotherapy and pharmacology* 2013.

Oh SC, Park YY, Park ES, et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. *Gut* 2012;61:1291-8.

Oh SC. Update of adjuvant chemotherapy for resected gastric cancer. *Journal of gastric cancer* 2012;12:3-6.

Kim ST, Park KH, Oh SC, et al. Varicella zoster virus infection during chemotherapy in solid cancer patients. *Oncology* 2012;82:126-30.

Kim ST, Park KH, Oh SC, et al. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients? *Asia-Pacific journal of clinical oncology* 2012;8:194-200.

Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? *Oncology* 2012;83:354-60.

Kim ST, Park KH, Oh SC, et al. Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer. *Cancer research and treatment : official journal of Korean Cancer Association* 2012;44:37-42.

Kim ST, Choi YJ, Park KH, et al. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2012;24:105-11.

Kang HN, Oh SC, Kim JS, Yoo YA. Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53. *Experimental cell research* 2012;318:539-49.

Choi YJ, Kim ST, Park KH, et al. The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. *Medical oncology (Northwood, London, England)* 2012;29:582-8.

Choi YH, Oh SC, Kim JS, et al. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. *Cancer chemotherapy and pharmacology* 2012;70:665-72.

Choi JG, Seo JH, Oh SC, Choi CW, Kim JS. A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. *Cancer research and treatment : official journal of Korean Cancer Association* 2012;44:127-32.

Yoo YA, Kang MH, Lee HJ, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. *Cancer research* 2011;71:7061-70.

Kim ST, Choi YJ, Park KH, et al. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. *Asia-Pacific journal of clinical oncology* 2011;7:82-7.

Kim ST, Choi YJ, Park KH, et al. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. *Chemotherapy* 2011;57:108-14.



Kang MH, Oh SC, Lee HJ, et al. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kappaB pathway, and MMP-9 expression. *Experimental cell research* 2011;317:1746-62.

Seo HY, Park JM, Park KH, et al. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. *Japanese journal of clinical oncology* 2010;40:1147-53.

Park Y, Kim DS, Park SJ, et al. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. *Leukemia research* 2010;34:294-300.

Park Y, Kang MH, Seo HY, et al. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. *Medical oncology (Northwood, London, England)* 2010;27:1192-9.

Park SJ, Choi IK, Seo HY, et al. Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer. *Oncology letters* 2010;1:51-5.

Park KH, Kim JS, Park Y, et al. Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. *Cancer chemotherapy and pharmacology* 2010;66:643-51.

Oh DY, Cha Y, Choi IS, et al. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. *Cancer chemotherapy and pharmacology* 2010;65:527-36.

Kim ST, Park KH, Oh SC, et al. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy. *Oncology* 2010;79:363-9.

Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. *Experimental cell research* 2010;316:24-37.

Kang EJ, Choi YJ, Kim JS, et al. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. *Asia-Pacific journal of clinical oncology* 2010;6:286-91.

Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. *Cancer chemotherapy and pharmacology* 2010;65:641-7.

Seo JH, Sung HJ, Park KH, et al. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy. *Investigational new drugs* 2009;27:67-73.

Seo HY, Kim DS, Choi YS, et al. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.

Cancer chemotherapy and pharmacology 2009;63:433-9.

Kim SH, Choi YS, Lee J, et al. Reliability and validity of the Hospice Quality of Life Scale for Korean cancer patients. *Journal of pain and symptom management* 2009;37:156-67.

Kang MH, Kang HN, Kim JL, Kim JS, Oh SC, Yoo YA. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. *Oncology reports* 2009;22:525-34.

Jo YM, Song JY, Hwang IS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. *Journal of medical virology* 2009;81:722-7.

Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. *Carcinogenesis* 2008;29:480-90.

Park Y, Kim JW, Kim DS, et al. The Bone Morphogenesis Protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer. *Cancer research and treatment : official journal of Korean Cancer Association* 2008;40:127-32.

Kim EB, Park Y, Park SJ, et al. Clinical factors related to suspected second primary lung cancer development in patients with head and neck cancer. *Cancer research and treatment : official journal of Korean Cancer Association* 2008;40:178-83.

Yoon SY, Sung HJ, Park KH, et al. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. *Acta haematologica* 2007;118:30-7.

Seo JH, Oh SC, Choi CW, et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. *Cancer chemotherapy and pharmacology* 2007;59:269-74.

Park SS, Kang SH, Park JM, et al. Expression of liver-intestine cadherin and its correlation with lymph node metastasis in gastric cancer: can it predict N stage preoperatively? *Annals of surgical oncology* 2007;14:94-9.

Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. *Acta haematologica* 2007;118:219-21.

Oh SC, Sur HY, Sung HJ, et al. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. *British journal of cancer* 2007;96:1514-9.

Jung HY, Sung JS, Whang YM, et al. Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population. *Journal of human genetics* 2007;52:668-74.

Choi IK, Seo HY, Sung HJ, et al. Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. *Medical oncology (Northwood,*

London, England) 2007;24:33-7.

Yoon SY, Lee YJ, Seo JH, et al. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. *Cell research* 2006;16:75-81.

Sung HJ, Kim SJ, Seo HY, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. *British journal of haematology* 2006;134:45-53.

Kim SJ, Seo HY, Choi JG, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. *Cancer chemotherapy and pharmacology* 2006;57:436-42.

Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. *Cancer research* 2005;65:4809-16.

Park KH, Choi IK, Kim SJ, et al. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. *Cancer* 2005;103:2338-43.

Oh SC, Park KH, Choi IK, et al. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. *British journal of cancer* 2005;92:827-31.

Oh SC, Choi CW, Kim BS, et al. NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case. *International journal of hematology* 2004;79:480-3.

Kim SJ, Choi IK, Park KH, et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. *Japanese journal of clinical oncology* 2004;34:184-90.

Choi IK, Kim BS, Lee KA, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. *American journal of hematology* 2004;77:366-9.

Choi CW, Lee J, Park KH, et al. Prevalence and characteristics of anemia in the elderly: cross-sectional study of three urban Korean population samples. *American journal of hematology* 2004;77:26-30.

Choi CW, Sung HJ, Park KH, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. *American journal of hematology* 2003;73:263-6.

Award

85th Japanese Gastric Cancer association, annual meeting : young investigator award

NF-kB dependents Sonic hedgehog upregulated MAP kinase signaling pathway and cell invasion